OTC: EKSO

Featured Story
I'm Still Bullish on Ekso Bionics Stock – Here's Why

By Keith Fitz-Gerald, Chief Investment Strategist, Money Map Report - August 21, 2015
Ekso Bionics stock was our first human augmentation recommendation, and it has drifted lower recently.
But the business case for EKSO's growth is very strong.
EKSO is crushing its rivals and hitting many milestones...

Article Index

I'm Still Bullish on Ekso Bionics Stock – Here's Why

By Keith Fitz-Gerald, Chief Investment Strategist, Money Map Report - August 21, 2015

Ekso Bionics stock was our first human augmentation recommendation, and it has drifted lower recently.

But the business case for EKSO's growth is very strong.

EKSO is crushing its rivals and hitting many milestones...

The Short Attack on Ekso Bionics (OTC: EKSO) Stock and How to Handle It

By Keith Fitz-Gerald, Chief Investment Strategist, Money Map Report - June 5, 2015

On June 2, Ekso Bionics Holdings Inc. (OTC: EKSO) stock dropped 24. 28% -- thanks to an anonymous individual writing under the name "The Pump Stopper" who launched a vicious attack on the stock.

But if you've been in this game long enough, you know what to look for and why stuff like this isn't a big deal in the grand scheme of things.

Here's why you shouldn't be worried...

This Little-Known Industry Is Producing the Fastest-Growing Stocks

By Kyle Anderson, Associate Editor, Money Morning • @KyleAndersonMM - April 10, 2015

Money Morning’s Chief Investment Strategist Keith Fitz-Gerald first told his readers about the incredible profit opportunity in the human augmentation market in October 2014.

Since then, it has provided some of the fastest-growing stocks on the market. And Fitz-Gerald sees the run continuing for years.

“No matter how many times I review the data or I rearrange the puzzle, this is THE trend of the next decade,” Fitz-Gerald said.

And now, the mainstream media is finally catching up with Fitz-Gerald’s predictions…

Score an Extra 655% with EKSO – Make Your Move Now

By Keith Fitz-Gerald, Chief Investment Strategist, Money Map Report - April 2, 2015

We've loved EKSO Bionics for some time now. It's revenue has gone up 80% since we first recommended it. Its exports surged 250% in one year.

And Sterne Agee kicked off coverage of the company with a "buy" rating and an initial price target of $1.75 per share.

Here's why EKSO should be your next profit play...

The Human Augmentation Market Just Got Red-Hot

By Keith Fitz-Gerald, Chief Investment Strategist, Money Map Report - March 13, 2015

The human augmentation market will be worth billions of dollars by 2020. It's growing at a rate of 43.52% a year. And some of our readers are already cashing in.

One of our favorite human augmentation stocks has returned 25% since it was first recommended last fall.

Here are the market’s top companies...

Make Any Investment Risk "Free" in One Move

By Keith Fitz-Gerald, Chief Investment Strategist, Money Map Report - February 23, 2015

Investment risk is part of the trading territory. Anyone offering 100% risk-free investments is lying. Right, Mr. Madoff?

Still, there's one tactic you can use to trade as close to "risk-free" as possible. It's gained our readers 100% returns in the process.

Here's what you need to know...

OTC: EKSO

Featured Story

I'm Still Bullish on Ekso Bionics Stock – Here's Why

Article Index

You may choose from these hot topics to start receiving our money-making recommendations in real time.

Interested in other topics? You can add more alerts below.